MWVC
HZNP

Morgens Waterfall Vintiadis & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,000
Closed -$842K – 39
2022
Q1 		$842K Buy
+8,000
New +$780K 0.53% 26

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's HZNP Position: Q2 2022 in Review

Morgens Waterfall Vintiadis & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 8,000 shares — an estimated $842K sold.

Morgens Waterfall Vintiadis & Co first reported a position in HZNP in Q1 2022 and held it in 1 quarter. The position peaked at $842K in Q1 2022. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

  • Morgens Waterfall Vintiadis & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 8,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $842K.
  • Morgens Waterfall Vintiadis & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022 and held it in 1 quarter.
  • Morgens Waterfall Vintiadis & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $842K in Q1 2022.
  • 616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q2 2022, filed 15 Aug 2022.